



COPIES OF PAPERS  
ORIGINALLY FILED

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on July 3, 2002.

By: Judith Muzyk Date: July 3, 2002  
Judith Muzyk

Docket No.: 242/9-1568

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

RECEIVED

7/8  
M.J.J  
8/6/02

Applicant: Roberto Valducci

Serial No.: 09/898,425

Group Art Unit: 1615

Filing Date: July 3, 2001

JUL 15 2002  
TECH CENTER 1600/2900

For: ORAL SOLID PHARMACEUTICAL FORMULATION WITH PH-  
DEPENDENT MULTIPHASIC RELEASE

Commissioner for Patents  
Washington, D.C. 20231

**AMENDMENT**

Sir:

In response to the Office Action dated March 4, 2002, please amend the above-identified application as follows:

**IN THE SPECIFICATION**

Page 3, replace the paragraph extending from lines 21-26 with the following paragraph:

Document EP 0 629 398 (Tanabe Seiyaku Co. Ltd.) refers to pharmaceutical preparations able to provide a controlled release of the active ingredient in the desired zone of the intestinal tract (duodenum, small intestine, colon, rectum), and anyway at a pH ≥ 5, through a proper choice of the coating, and checking, furthermore, the dissolution speed of the drug itself. Among the many coatings indicated as useful, Eudragit L, poly(methacrylic acid-co-methyl methacrylate), 1:1, 135,000 MW, available from Rohm Pharma polymers) and Eudragit S poly(methacrylic acid-co-methylmethacrylate), 1:2, 135,000 MW, available from Rohm Pharma Polymers are mentioned.